Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.55
Bid: 6.20
Ask: 6.90
Change: 0.30 (4.80%)
Spread: 0.70 (11.29%)
Open: 6.25
High: 6.55
Low: 6.25
Prev. Close: 6.25
KMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kromek receives $2.1m security screening order

26 Mar 2024 07:00

RNS Number : 2389I
Kromek Group PLC
26 March 2024
 

26 March 2024

 

Kromek Group plc

("Kromek" or the "Group")

 

Kromek receives $2.1m security screening order

New order from long-standing OEM customer

 

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that it has received a $2.1m order from an existing US-based OEM customer that is an emerging leader and global company in the homeland security marketplace.

 

The order is for the supply of key detector components for incorporation into the customers' advanced security screening system for the detection of explosives. Delivery will commence in the current year and complete in the first half of FY 2025. The Group has been supplying this customer since 2017 when it was awarded a five-year delivery contract, following the completion of an R&D phase to design components to meet the customer's requirements, and it expects to enter another long-term delivery contract.

 

Arnab Basu, CEO of Kromek, said: "We are pleased to have received this latest order from a long-standing customer in the security screening market. It demonstrates the strength of our advanced imaging business where, after an initial design phase, we continue to receive orders for years to come. It also adds to the growing pipeline for FY 2025, which we expect to be a year of further growth. In addition, with the global aviation market now recovering, we expect another long-term delivery contract in due course, which will provide enhanced visibility into 2025 and beyond. We look forward to updating the market on our progress." 

 

 

For further information, please contact: 

? 

Kromek Group plc 

Arnab Basu, CEO 

Paul Farquhar, CFO 

+44 (0)1740 626 060

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)? 

? 

Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance 

Tim Redfern - ECM 

+44 (0)20 7220?0500 

 

Michael Johnson/Tamar Cranford-Smith - Sales

 

Gracechurch Group (Financial PR) 

Harry Chathli/Claire Norbury/Henry Gamble

+44 (0)20 4582 3500

 

 

Kromek Group plc 

 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

 

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

 

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

 

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSEIEFIELSEFD
Date   Source Headline
2nd Aug 20227:00 amRNSFinal Results
2nd Aug 20227:00 amRNSKromek wins over $750k in new orders
7th Jul 20227:00 amRNSKromek enters agreement with Smiths Detection Inc.
25th May 20227:00 amRNSNew Nuclear Security order from US federal entity
16th May 202212:07 pmRNSDirector Share Purchase
16th May 20227:00 amRNSBusiness and Trading Update
16th May 20227:00 amRNSAppointment of Nominated Adviser and Broker
4th Apr 20227:00 amRNSNew £1.7m CBRN contract
18th Jan 20227:00 amRNSInterim Results
17th Dec 20214:41 pmRNSSecond Price Monitoring Extn
17th Dec 20214:35 pmRNSPrice Monitoring Extension
14th Dec 20217:00 amRNSNotice of Results
26th Oct 20217:00 amRNSKromek awarded contract by US based OEM customer
29th Sep 20213:14 pmRNSHolding(s) in Company
27th Sep 20211:47 pmRNSDirector Share Purchase
23rd Sep 20217:00 amRNSNuclear security contract from US federal entity
8th Sep 202111:09 amRNSResult of AGM
13th Aug 20213:48 pmRNSNotice of AGM and Publication of Annual Report
3rd Aug 202112:25 pmRNSHolding(s) in Company
15th Jul 202111:05 amRNSSecond Price Monitoring Extn
15th Jul 202111:00 amRNSPrice Monitoring Extension
14th Jul 20217:00 amRNSFinal Results
14th Jul 20217:00 amRNSNew Contracts
1st Jul 20217:00 amRNSNotice of Results
24th Jun 20214:41 pmRNSSecond Price Monitoring Extn
24th Jun 20214:36 pmRNSPrice Monitoring Extension
14th Jun 20217:00 amRNSKromek awarded new DARPA bio-threat contract
12th May 20212:50 pmRNSDirector Share Purchase
11th May 20217:00 amRNSBusiness and Trading Update
21st Apr 20214:32 pmRNSHolding(s) in Company
9th Mar 20217:00 amRNSKromek awarded Nuclear Detection contract
4th Mar 20211:32 pmRNSHolding(s) in Company
2nd Mar 20218:30 amRNSPDMR Dealings
1st Mar 20212:53 pmRNSResults of Placing, Open Offer and General Meeting
1st Mar 20217:00 amRNSNew Medical Screening and Nuclear Security orders
19th Feb 20212:05 pmRNSSecond Price Monitoring Extn
19th Feb 20212:01 pmRNSPrice Monitoring Extension
15th Feb 20217:00 amRNSPosting of Circular
12th Feb 202111:05 amRNSSecond Price Monitoring Extn
12th Feb 202111:00 amRNSPrice Monitoring Extension
12th Feb 202110:30 amRNSPlacing and Open Offer to raise up to £13 million
4th Feb 20212:00 pmRNSIssue of Equity and Total Voting Rights
26th Jan 20215:15 pmRNSHolding(s) in Company
22nd Jan 20214:41 pmRNSSecond Price Monitoring Extn
22nd Jan 20214:35 pmRNSPrice Monitoring Extension
22nd Jan 20212:05 pmRNSSecond Price Monitoring Extn
22nd Jan 20212:00 pmRNSPrice Monitoring Extension
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:35 pmRNSPrice Monitoring Extension
14th Jan 20219:35 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.